Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells.

Hladíková K, Koucký V, Bouček J, Laco J, Grega M, Hodek M, Zábrodský M, Vošmik M, Rozkošová K, Vošmiková H, Čelakovský P, Chrobok V, Ryška A, Špíšek R, Fialová A.

J Immunother Cancer. 2019 Oct 17;7(1):261. doi: 10.1186/s40425-019-0726-6.

2.

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.

Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, Bilkova P, Holubova M, Chen X, Mikyskova R, Reinis M, Kovar M, Tomalova B, Kline JP, Galluzzi L, Spisek R, Fucikova J.

Haematologica. 2019 Oct 3. pii: haematol.2019.223933. doi: 10.3324/haematol.2019.223933. [Epub ahead of print]

3.

Radiotherapy in Combination With Cytokine Treatment.

Palata O, Hradilova Podzimkova N, Nedvedova E, Umprecht A, Sadilkova L, Palova Jelinkova L, Spisek R, Adkins I.

Front Oncol. 2019 May 22;9:367. doi: 10.3389/fonc.2019.00367. eCollection 2019. Review.

4.

Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?

Funda DP, Palová-Jelínková L, Goliáš J, Kroulíková Z, Fajstová A, Hudcovic T, Špíšek R.

Front Immunol. 2019 May 14;10:967. doi: 10.3389/fimmu.2019.00967. eCollection 2019. Review.

5.

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.

Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialova A, Pineau J, Gey A, Tartour E, Ryska A, Galluzzi L, Spisek R.

Clin Cancer Res. 2019 Aug 1;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. Epub 2019 May 10.

PMID:
31076549
6.

Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?

Grohová A, Dáňová K, Špíšek R, Palová-Jelínková L.

Front Immunol. 2019 Feb 5;10:79. doi: 10.3389/fimmu.2019.00079. eCollection 2019. Review.

7.

Tumour devascularisation as a potential immunotherapeutic strategy.

Buchler T, Vasek P, Spisek R, Skrobanek P, Horejsi V.

Oncoimmunology. 2018 Oct 11;8(1):e1526614. doi: 10.1080/2162402X.2018.1526614. eCollection 2019.

8.

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Review.

9.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Review.

10.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

11.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, Fridman WH, Ryska A, Galluzzi L, Spisek R, Fucikova J.

J Immunother Cancer. 2018 Dec 4;6(1):139. doi: 10.1186/s40425-018-0446-3.

12.

RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment.

Čermák V, Gandalovičová A, Merta L, Fučíková J, Špíšek R, Rösel D, Brábek J.

Sci Data. 2018 Oct 2;5:180198. doi: 10.1038/sdata.2018.198.

13.

Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.

Hladíková K, Partlová S, Koucký V, Bouček J, Fonteneau JF, Zábrodský M, Tachezy R, Grega M, Špíšek R, Fialová A.

Oral Oncol. 2018 Jul;82:75-82. doi: 10.1016/j.oraloncology.2018.05.010. Epub 2018 May 26.

PMID:
29909905
14.

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. Review.

15.
16.

High hydrostatic pressure in cancer immunotherapy and biomedicine.

Adkins I, Hradilova N, Palata O, Sadilkova L, Palova-Jelinkova L, Spisek R.

Biotechnol Adv. 2018 May - Jun;36(3):577-582. doi: 10.1016/j.biotechadv.2018.01.015. Epub 2018 Feb 1. Review.

PMID:
29409785
17.

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.

Mikyskova R, Indrova M, Stepanek I, Kanchev I, Bieblova J, Vosahlikova S, Moserova I, Truxova I, Fucikova J, Bartunkova J, Spisek R, Sedlacek R, Reinis M.

Oncoimmunology. 2017 Aug 24;6(12):e1362528. doi: 10.1080/2162402X.2017.1362528. eCollection 2017.

18.

Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer.

Fucikova J, Kasikova L, Truxova I, Laco J, Skapa P, Ryska A, Spisek R.

Immunol Lett. 2018 Jan;193:25-34. doi: 10.1016/j.imlet.2017.11.006. Epub 2017 Nov 23. Review.

PMID:
29175313
19.

Trial watch: Immune checkpoint blockers for cancer therapy.

Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237. eCollection 2017. Review.

20.

Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.

Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R, Fialova A, Vavrova K, Sochorova K, Rozkova D, Spisek R, Bartunkova J.

Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25.

PMID:
28948333
21.

Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells.

Adkins I, Sadilkova L, Hradilova N, Tomala J, Kovar M, Spisek R.

Oncoimmunology. 2017 Mar 31;6(5):e1311433. doi: 10.1080/2162402X.2017.1311433. eCollection 2017.

22.

High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy.

Urbanova L, Hradilova N, Moserova I, Vosahlikova S, Sadilkova L, Hensler M, Spisek R, Adkins I.

Immunol Lett. 2017 Jul;187:27-34. doi: 10.1016/j.imlet.2017.05.005. Epub 2017 May 8.

PMID:
28495513
23.

Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.

Truxova I, Hensler M, Skapa P, Halaska MJ, Laco J, Ryska A, Spisek R, Fucikova J.

Int Rev Cell Mol Biol. 2017;330:115-156. doi: 10.1016/bs.ircmb.2016.09.003. Epub 2016 Nov 29. Review.

PMID:
28215530
24.

Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death.

Moserova I, Truxova I, Garg AD, Tomala J, Agostinis P, Cartron PF, Vosahlikova S, Kovar M, Spisek R, Fucikova J.

Oncoimmunology. 2016 Nov 18;6(1):e1258505. doi: 10.1080/2162402X.2016.1258505. eCollection 2017.

25.

Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.

Hradilova N, Sadilkova L, Palata O, Mysikova D, Mrazkova H, Lischke R, Spisek R, Adkins I.

PLoS One. 2017 Feb 10;12(2):e0171539. doi: 10.1371/journal.pone.0171539. eCollection 2017.

26.

Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells.

Dáňová K, Grohová A, Strnadová P, Funda DP, Šumník Z, Lebl J, Cinek O, Průhová Š, Koloušková S, Obermannová B, Petruželková L, Šedivá A, Fundová P, Buschard K, Špíšek R, Palová-Jelínková L.

J Immunol. 2017 Jan 15;198(2):729-740. doi: 10.4049/jimmunol.1600676. Epub 2016 Dec 7.

27.

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.

Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R.

Blood. 2016 Dec 29;128(26):3113-3124. doi: 10.1182/blood-2016-08-731737. Epub 2016 Nov 1.

28.

Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.

Myšíková D, Adkins I, Hradilová N, Palata O, Šimonek J, Pozniak J, Kolařík J, Skallová-Fialová A, Špíšek R, Lischke R.

J Thorac Oncol. 2017 Feb;12(2):249-257. doi: 10.1016/j.jtho.2016.09.136. Epub 2016 Oct 25.

29.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

30.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

31.

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.

Kloudová K, Hromádková H, Partlová S, Brtnický T, Rob L, Bartůňková J, Hensler M, Halaška MJ, Špíšek R, Fialová A.

Oncotarget. 2016 Jul 19;7(29):46120-46126. doi: 10.18632/oncotarget.10028.

32.

Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients.

Hensler M, Vančurová I, Becht E, Palata O, Strnad P, Tesařová P, Čabiňaková M, Švec D, Kubista M, Bartůňková J, Špíšek R, Sojka L.

Oncoimmunology. 2015 Dec 10;5(4):e1102827. eCollection 2016 Apr.

33.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

34.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

35.

Trial Watch-Immunostimulation with cytokines in cancer therapy.

Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1115942. eCollection 2016 Feb. Review.

36.

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.

Mikyšková R, Štěpánek I, Indrová M, Bieblová J, Šímová J, Truxová I, Moserová I, Fučíková J, Bartůňková J, Špíšek R, Reiniš M.

Int J Oncol. 2016 Mar;48(3):953-64. doi: 10.3892/ijo.2015.3314. Epub 2015 Dec 29.

37.

[Immune System in Patients with Head and Neck Carcinoma].

Partlová S, Bouček J, Kloudová K, Zábrodský M, Špíšek R, Fialová A.

Klin Onkol. 2015;28 Suppl 4:4S86-94. Review. Czech.

PMID:
26647896
38.

[The Concept of Immunogenic Cell Death in Antitumor Immunity].

Fučíková J, Bartůňková J, Špíšek R.

Klin Onkol. 2015;28 Suppl 4:4S48-55. Review. Czech.

PMID:
26647889
39.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

40.

Trial Watch: Adoptive cell transfer for oncological indications.

Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 May 5;4(11):e1046673. eCollection 2015 Nov. Review.

41.

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.

Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R.

Front Immunol. 2015 Aug 7;6:402. doi: 10.3389/fimmu.2015.00402. eCollection 2015. Review.

42.

Trial watch: Naked and vectored DNA-based anticancer vaccines.

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Apr 2;4(5):e1026531. eCollection 2015 May.

43.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.

44.

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008814. eCollection 2015 Apr. Review.

45.

Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death".

Bezu L, Gomes-da-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G.

Front Immunol. 2015 Jun 1;6:275. doi: 10.3389/fimmu.2015.00275. eCollection 2015.

46.

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J.

Oncotarget. 2015 Jul 20;6(20):18192-205.

47.
48.

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Adkins I, Fucikova J, Garg AD, Agostinis P, Špíšek R.

Oncoimmunology. 2015 Jan 7;3(12):e968434. eCollection 2014 Dec. Review.

49.

Combinatorial strategies for the induction of immunogenic cell death.

Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G.

Front Immunol. 2015 Apr 24;6:187. doi: 10.3389/fimmu.2015.00187. eCollection 2015. Review. Erratum in: Front Immunol. 2015;6:275.

50.

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.

Partlová S, Bouček J, Kloudová K, Lukešová E, Zábrodský M, Grega M, Fučíková J, Truxová I, Tachezy R, Špíšek R, Fialová A.

Oncoimmunology. 2015 Jan 30;4(1):e965570. eCollection 2015 Jan.

Supplemental Content

Loading ...
Support Center